Lyell Immunopharma Inc (LYEL) — Financial Flexibility Index
Lyell Immunopharma Inc (LYEL) has a Financial Flexibility Index of -0.35x as of December 2025. Free cash flow of $-31.88 Million (operating CF $-32.25 Million minus capex $366.00K) represents 0% of total liabilities ($91.85 Million). Check Lyell Immunopharma Inc (LYEL) strategic investment index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lyell Immunopharma Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Lyell Immunopharma Inc across 7 annual periods. See Lyell Immunopharma Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Lyell Immunopharma Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Lyell Immunopharma Inc. For the full company profile including market capitalisation, see LYEL stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.62x | $-149.24 Million | $-150.02 Million | $91.85 Million | ▼ -8.4% |
| 2024 | -1.50x | $-161.93 Million | $-162.39 Million | $108.03 Million | ▲ +11.5% |
| 2023 | -1.69x | $-161.01 Million | $-163.69 Million | $95.08 Million | ▼ -21.6% |
| 2022 | -1.39x | $-145.28 Million | $-169.56 Million | $104.31 Million | ▼ -353.1% |
| 2021 | -0.31x | $-60.74 Million | $-126.25 Million | $197.62 Million | ▲ +46.7% |
| 2020 | -0.58x | $-109.39 Million | $-160.87 Million | $189.84 Million | ▼ -253.2% |
| 2019 | 0.38x | $55.52 Million | $39.47 Million | $147.58 Million | — |